REACH

Realizing Effectiveness Across Continents with Hydroxyurea (REACH) is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed Sudden Cardiac Arrest (SCA) between 12 months and 10 years. objectives of the study include:

1. To assess the feasibility of conducting a prospective research study using hydroxyurea therapy for SCA in sub-Saharan Africa (including adherence to monthly clinic visits and laboratory assessments, and medication compliance)
2. To monitor the safety of hydroxyurea therapy, specifically documenting haematological toxicities (cytopenia) and serious infections (bacterial and malarial)
3. To evaluate the benefits of hydroxyurea therapy, using both laboratory (e.g., foetal haemoglobin, haemoglobin, white blood cell count) and clinical parameters (e.g., pain, hospitalization, growth)